Head of Investor Relations

Job Description

The following position is for Alkermes, Inc.

Recently, Alkermes announced its intention to explore a separation of its oncology business into an independent, publicly-traded company with assets ranging from pre-clinal to pivotal stage development. The new hire for this position will join Alkermes, but in the event the separation of the oncology business occurs (which, if completed, would likely occur in the second half of 2023), the expectation would be that the employee would become part of the Corporate Affairs/Investor Relations department within the newly-formed oncology company supporting the development of biological drug products.

Head of Corporate Affairs and Investor Relations

Job Description:

Reporting to the CFO, the Head of Investor Relations will be responsible for the development and implementation of Mural Oncology's investor relations and corporate affairs strategies, plans and tactics to ensure valuation appropriately reflects potential of the business and to help raise the profile of Mural Oncology as a leading scientific organization and a patient-centered leader in immuno-oncology.

The individual will be responsible for creating the company's IR strategy, framework, tactics, and communication materials to effectively articulate and support the company's business and scientific objectives. Will be responsible for building new and managing existing relationship with the equity research and investor community. The Head of Investor Relations and Corporate Affairs will oversee the corporate communications and patient advocacy functions. They will also be responsible for all corporate internal and external communications. Primary responsibilities include driving awareness and understanding of Mural Oncology's R&D expertise, strategy and pipeline assets; and communicating internally and externally about the company's assets, people, science and progress.

This individual will serve as a primary external spokesperson for Mural Oncology. This position requires close collaboration with Clinical Development, Discovery, Research, Medical Affairs, Finance and Legal.

About Us

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com

Alkermes, Inc. is an equal employment opportunity employer and does not discriminate against any applicant because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, gender expression and identity, disability, genetic information, veteran status, military status, application for military service or any other class protected by state or federal law. Alkermes also complies with all work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Alkermes is an E-Verify employer.